Drug intelligence / Profile preview

4-hydroxytamoxifen + retinoic acid

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

This is a combination of two small molecule drugs—4-hydroxytamoxifen and retinoic acid—investigated primarily for their synergistic anti-tumor effects in breast cancer models. - **4-hydroxytamoxifen** is the active metabolite of tamoxifen, a selective estrogen receptor modulator (SERM) that acts as an antagonist on estrogen receptors in breast tissue. - **Retinoic acid** (commonly all-trans-retinoic acid or ATRA) is a vitamin A derivative that regulates gene expression by activating nuclear retinoic acid receptors (RARs), influencing cell differentiation and proliferation.

Other names: OHT + RA4-OHT + RAhydroxytamoxifen plus retinoic acid

Targets

ESRRG (Estrogen-related receptor gamma)RARA (Retinoic acid receptor alpha)ESR1 (ERα)

Beyond the preview

Go deeper on 4-hydroxytamoxifen + retinoic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 4-hydroxytamoxifen + retinoic acid.

Explore the full profile